OncoCyte (NASDAQ:OCX) Earns Sell Rating from Analysts at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of OncoCyte (NASDAQ:OCX) in a report released on Wednesday. The brokerage set a “sell” rating on the stock.

Several other equities research analysts also recently weighed in on OCX. Stephens reissued an “equal weight” rating and set a $4.00 price objective on shares of OncoCyte in a report on Wednesday, April 17th. Benchmark reaffirmed a “speculative buy” rating and set a $5.00 target price on shares of OncoCyte in a report on Monday, April 15th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, OncoCyte currently has a consensus rating of “Hold” and a consensus target price of $3.90.

OncoCyte Price Performance

NASDAQ OCX opened at $2.46 on Wednesday. OncoCyte has a twelve month low of $2.08 and a twelve month high of $6.20. The business’s fifty day moving average is $2.93 and its 200 day moving average is $3.05.

Insiders Place Their Bets

In other OncoCyte news, major shareholder Broadwood Partners, L.P. acquired 2,420,000 shares of the stock in a transaction dated Thursday, April 11th. The stock was purchased at an average cost of $2.92 per share, with a total value of $7,066,400.00. Following the transaction, the insider now owns 4,929,066 shares in the company, valued at approximately $14,392,872.72. The acquisition was disclosed in a filing with the SEC, which is available at this link. In other OncoCyte news, major shareholder Broadwood Partners, L.P. acquired 2,420,000 shares of the stock in a transaction dated Thursday, April 11th. The stock was purchased at an average cost of $2.92 per share, with a total value of $7,066,400.00. Following the transaction, the insider now owns 4,929,066 shares in the company, valued at approximately $14,392,872.72. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, Director Andrew Arno acquired 33,898 shares of the stock in a transaction dated Thursday, April 11th. The stock was acquired at an average cost of $2.95 per share, with a total value of $99,999.10. Following the completion of the transaction, the director now owns 69,054 shares in the company, valued at approximately $203,709.30. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 2,457,288 shares of company stock valued at $7,176,400. 1.94% of the stock is currently owned by company insiders.

About OncoCyte

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.